Floatz logo

Epcam Car-T

Advanced Gastric Cancer

Zhejiang UniversityCell therapyPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
89/ 100

Competitive context

282 Active assets in the Advanced Gastric Cancer cohort.

Asset / SponsorPhaseRating
Rivoceranib
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase 4BBB
FLUOROURACILUM
I-Mab Biopharma US Limited
Phase 4BB
Eloxatin
Qilu Pharmaceutical Co., Ltd.
Phase 3BB
Irinotecan
Shenzhen Xinhe Biomedical
Phase 4BB
Epirubicin
Rondo Therapeutics
Phase 3BB

View all 50 →

Same molecule, other indications

Epcam Car-T is also rated in:

hepatocellular carcinomaDormant
CC
Indicative ·
41 / 100
View asset →
colorectal cancerDormant
CC
Indicative ·
41 / 100
View asset →
malignant pancreatic neoplasmDormant
CC
Indicative ·
41 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →